Medicines & Healthcare products Regulatory Agency

MHRA

Public Assessment Report

National Procedure

Eladynos 80 micrograms/dose solution for injection in pre-filled pen

abaloparatide

PLGB 56979/0001

Radius Health (Ireland) Limited

LAY SUMMARY

Eladynos 80 micrograms/dose solution for injection in pre-filled pen abaloparatide

This is a summary of the Public Assessment Report (PAR) for Eladynos 80 micrograms/dose solution for injection in pre-filled pen. It explains how this product was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use this product.

This product will be referred to as Eladynos in this lay summary for ease of reading.

This product has been authorised by MHRA for Great Britain (consisting of England, Scotland and Wales). In coming to its decision, MHRA has relied on a European Commission (EC) decision on 12 December 2022 (EMEA/H/C/005928/0000), in accordance with the advice from the Committee for Medicinal Products for Human Use (CHMP). This is known as the EC Decision Reliance Procedure.

This application was approved under Regulation 50 of the Human Medicines Regulation 2012, as amended (previously Article 8.3 of Directive 2001/83/EC, as amended).

For practical information about using Eladynos, patients should read the Patient Information Leaflet (PIL) or contact their doctor or pharmacist.

What is Eladynos and what is it used for?
This medicine is used to treat osteoporosis in women after menopause. Osteoporosis is especially common in women after menopause. The disease causes bones to become thin and fragile. If the patient has osteoporosis, they are more likely to break bones, especially in the spine, hips and wrists.

How does Eladynos work?
Eladynos contains the active substance, abaloparatide, which make bone stronger and less likely to break.

How is Eladynos used?
The pharmaceutical form of this medicine is a solution for injection (injection).

The recommended dose is one injection (80 micrograms) once daily administered under the skin in the lower abdomen (belly). See grey shaded area of the first figure in Step 5 in the "Instructions for use" at the end of the package leaflet.

Preferably, the patient should inject Elyadynos at the same time each day to help them remember to use their medicine.

The patient should not inject Eladynos in the same place on their belly on consecutive days. They should change where they inject this medicine each day to reduce the risk of injection site reactions. The patient should only inject into clear skin. The patient should not inject into areas where the skin is tender, bruised, red, scaly or hard. They should avoid areas with scars or stretch marks.

The patient should carefully follow the "Instructions for use" at the end of the package leaflet.

The doctor may advise their patient to take supplementary calcium and vitamin D. The patient's doctor will tell the patient how much they should take each day.

Duration of use
The patient should inject Eladynos each day for as long as prescribed by their doctor. The maximum total duration of treatment with Eladynos should not exceed 18 months.

For further information on how Eladynos is used, refer to the PIL and Summary of Product Characteristics (SmPC) available on the Medicines and Healthcare products Regulatory Agency (MHRA) website.

This medicine can only be obtained with a prescription.

The patient should always take the medicine exactly as their doctor/pharmacist has told them. The patient should check with their doctor or pharmacist if they are not sure.

What benefits of Eladynos have been shown in studies?
In a main study involving 2,070 patients, Eladynos was more effective than placebo (a dummy treatment) in reducing fractures in the spine in women with osteoporosis who have been through menopause.

After 18 months, 0.5% of those treated with Eladynos had a new spinal fracture compared with 4.2% in the group who received placebo.

What are the possible side effects of Eladynos?
The most common side effects with Eladynos (which may affect more than 1 in 10 people) are:
• increase in calcium level seen in urine tests
• dizziness – see section 2 "Warnings and Precautions" of the package leaflet.

For the full list of all side effects reported with this medicine, see Section 4 of the PIL or the SmPC available on the MHRA website.

If a patient gets any side effects, they should talk to their doctor, pharmacist or nurse. This includes any possible side effects not listed in the product information or the PIL that comes with the medicine. Patients can also report suspected side effects themselves, or a report can be made on their behalf by someone else who cares for them, directly via the Yellow Card scheme at https://yellowcard.mhra.gov.uk or search for 'MHRA Yellow Card' online. By reporting side effects, patients can help provide more information on the safety of this medicine.

Why was Eladynos approved?
There is a need for new safe and effective medicines for preventing fractures in women who have been through menopause and have osteoporosis. The main study showed that Eladynos reduces the risk of spinal fractures in these patients. The results also suggest that it may reduce the risk of non-spinal fractures.

Regarding safety, the side effects of Eladynos were mostly mild to moderate. Although Eladynos can increase the heart rate after injection, there is no evidence that it causes major

heart problems. As a precaution, doctors should assess the risks before starting treatment and should monitor the heart function of patients with cardiovascular disease (affecting the heart and blood circulation).

The MHRA decided that Eladynos' benefits are greater than the risks and recommended that this medicine can be approved for use.

Eladynos has been authorised with the condition to perform further studies to minimise the risk. See section below "What measures are being taken to ensure the safe and effective use of Eladynos?"

What measures are being taken to ensure the safe and effective use of Eladynos?
As for all newly authorised medicines, a Risk Management Plan (RMP) has been developed for Eladynos. The RMP details the important risks of Eladynos, how these risks can be minimised, any uncertainties about Eladynos (missing information), and how more information will be obtained about the important risks and uncertainties.

The following safety concerns have been recognised for Eladynos:

Summary of safety concerns	
Important identified risks	None
Important potential risks	Osteosarcoma Serious cardiovascular events (i.e. MACE, arrhythmia)
Missing information	None

The information included in the SmPC and the PIL is compiled based on the available quality, non-clinical and clinical data, and includes appropriate precautions to be followed by healthcare professionals and patients. Side effects of Eladynos are continuously monitored and reviewed including all reports of suspected side-effects from patients, their carers, and healthcare professionals.

In addition to the safety information provided in the Eladynos product information, the Marketing Authorisation Holder (MAH) has committed to additional pharmacovigilance activity through a post-authorisation safety study to further evaluate serious cardiovascular events for Eladynos.

An RMP and a summary of the pharmacovigilance system have been provided with this application and are satisfactory.

Other information about Eladynos
A marketing authorisation was granted in Great Britain on 27 March 2023.

The full PAR for Eladynos follows this summary.

This summary was last updated in June 2023.

TABLE OF CONTENTS

I. INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the Medicines and Healthcare products Regulatory Agency (MHRA) considered that the application for Eladynos 80 micrograms/dose solution for injection in pre-filled pen (PLGB 56979/0001) could be approved.

The product is approved for the following indication:

- treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1 of the Summary of Characteristics (SmPC)).

The active substance, abaloparatide, is a 34 amino acid peptide that shares 41% homology to parathyroid hormone [PTH(1 34)] and 76% homology to parathyroid hormone related peptide [PTHrP(1 34)], and is an activator of the PTH1 receptor signalling pathway. Abaloparatide stimulates new bone formation on trabecular and cortical bone surfaces by stimulation of osteoblastic activity. Abaloparatide causes transient and limited increases in bone resorption and increases bone density.

This product has been authorised by MHRA for Great Britain (consisting of England, Scotland and Wales). In coming to its decision, MHRA has relied on a European Commission (EC) decision on 12 December 2022 (EMEA/H/C/005928/0000), in accordance with the advice from the Committee for Medicinal Products for Human Use (CHMP).

For the scientific discussion of the quality, non-clinical and clinical assessment conducted by the European Medicines Agency (EMA), please refer to the European Public Assessment Report, available on the EMA website.

In line with the legal requirements for children's medicines, the application included a licensing authority decision on the agreement of a full product specific waiver (EMEA-001667-PIP0l-14).

The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for this product at all sites responsible for the manufacture, assembly and batch release of this product.

A Risk Management Plan (RMP) and a summary of the pharmacovigilance system have been provided with this application and are satisfactory.

A marketing authorisation was granted on 27 March 2023.

II. PRODUCT INFORMATION

SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

The SmPC is in line with current guidelines and was satisfactory.

PATIENT INFORMATION LEAFLET (PIL)

The PIL is in line with current guidelines and is satisfactory.

LABEL

The labelling is in line with current guidelines and is satisfactory.

III. QUALITY ASPECTS

The MHRA considered that the quality data submitted for this application is satisfactory.

The grant of a marketing authorisation was recommended.

IV. NON-CLINICAL ASPECTS

The MHRA considered that the non-clinical data submitted for this application is satisfactory.

The grant of a marketing authorisation was recommended.

V. CLINICAL ASPECTS

The MHRA considered that the clinical data submitted for this application is satisfactory.

The grant of a marketing authorisation was recommended.

VI. RISK MANAGEMENT PLAN (RMP)

The applicant has submitted an RMP, in accordance with the requirements of Regulation 182 of The Human Medicines Regulation 2012, as amended. In addition to routine pharmacovigilance and risk minimisation measures, the following additional: pharmacovigilance measure has been proposed:

Summary Table of Additional Pharmacovigilance Activities

Study Status	Summary of objectives	Safety concerns addressed	Milestones	Due dates
Category 3 - Required additional pharmacovigilance activities				
Abaloparatide PASS: European non-interventional post-authorization safety study (PASS) to assess serious cardiovascular events of MI, stroke, all-cause and cardiovascular mortality, and arrhythmias for abaloparatide. Planned	To evaluate the potential risk of serious CV events of MI, stroke, all-cause mortality including CV death and arrhythmias associated with the use of abaloparatide in routine clinical practice compared with other available OP medications	Serious cardiovascular events (i.e. MACE, arrhythmia)	Final PASS protocol submission	Within 3 months post abaloparatide approval
			Interim reports on an annual basis	For the entire study period until the final study report is submitted
			Final report	2029-2030

This is acceptable.

VII. USER CONSULTATION

A full colour mock-up of the PIL has been provided with the application, in accordance with legal requirements.

The PIL has been evaluated via a user consultation study in accordance with legal requirements. The results show that the PIL meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

VIII. OVERALL CONCLUSION, BENEFIT/RISK AND RECOMMENDATION

The quality of the product is acceptable. The non-clinical and clinical data submitted have shown the positive benefit/risk of this product in the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

The SmPC, PIL and labelling are satisfactory.

In accordance with legal requirements, the current approved UK versions of the SmPC and PIL for this product are available on the MHRA website.

The following text is the currently approved label text. No label mock-ups have been provided for this product. In accordance with legal requirements, this product shall not be marketed until approval of the full-colour label mock-ups has been obtained.

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON

1. NAME OF THE MEDICINAL PRODUCT

Eladynos 80 micrograms/dose solution for injection in pre-filled pen
abaloparatide

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each dose of 40 microliters contains 80 micrograms of abaloparatide.

3. LIST OF EXCIPIENTS

Excipients: phenol, water for injections, sodium acetate trihydrate (for pH adjustment), acetic acid (for pH adjustment). See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection
1 pre-filled pen with 30 doses in 1.5 mL solution

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Subcutaneous use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
After first use, store below 25 °C and discard after 30 days.
Date of Opening (Day 1): _____

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Radius Health (Ireland) Ltd.
13 Classon House
Dundrum Business Park, Dundrum
Dublin D14 W9Y3
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

PLGB 56979/0001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Prescription only medicine

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Eladynos

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

PEN LABEL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Eladynos 80 mcg/dose injection
abaloparatide
SC

2. METHOD OF ADMINISTRATION

Subcutaneous use

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1.5 mL
30 doses

6. OTHER

TABLE OF CONTENT OF THE PAR UPDATE

Steps taken after the initial procedure with an influence on the Public Assessment Report (non-safety variations of clinical significance).

Please note that only non-safety variations of clinical significance are recorded below and in the annexes to this PAR. The assessment of safety variations, where significant changes are made, is recorded on the MHRA website or European Medicines Agency (EMA) website. Minor changes to the marketing authorisation are recorded in the current SmPC and/or PIL available on the MHRA website.

Application type	**Scope**	**Product information affected**	**Date of grant**	**Outcome**	**Assessment report attached Y/N**

/